Medpace (NASDAQ:MEDP) Downgraded to "Neutral" Rating by Rothschild & Co Redburn

Key Points

• Medpace was downgraded from a "buy" rating to a "neutral" rating by Rothschild & Co Redburn, with a price target of $474.00, indicating a potential upside of only 0.14% from its previous close.
• Despite recent downgrades, Medpace has seen positive financial performance, reporting earnings of $3.10 per share, surpassing analysts' expectations, and a revenue increase of 14.2% year-over-year.
• Insider trading activity shows significant share sales by executives, with CFO Kevin M. Brady reducing his position by 66.67% after selling 12,000 shares.

Medpace (NASDAQ:MEDP - Get Free Report) was downgraded by research analysts at Rothschild & Co Redburn from a "buy" rating to a "neutral" rating in a research report issued on Wednesday, Marketbeat.com reports. They currently have a $474.00 target price on the stock, up from their prior target price of $342.00. Rothschild & Co Redburn's target price indicates a potential downside of 2.67% from the stock's current price.

A number of other research firms have also recently weighed in on MEDP. Mizuho upped their price target on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. UBS Group cut Medpace from a "neutral" rating to a "sell" rating and upped their price target for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Barclays upped their price target on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Cowen cut Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Finally, Truist Financial upped their price target on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Medpace currently has a consensus rating of "Reduce" and an average price target of $412.73.

Medpace Price Performance

NASDAQ MEDP traded up $4.64 during mid-day trading on Wednesday, hitting $486.98. The company's stock had a trading volume of 233,792 shares, compared to its average volume of 316,283. Medpace has a 52-week low of $250.05 and a 52-week high of $501.30. The stock's fifty day simple moving average is $412.68 and its two-hundred day simple moving average is $344.19. The firm has a market capitalization of $13.68 billion, a P/E ratio of 36.21, a price-to-earnings-growth ratio of 3.06 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same quarter last year, the firm posted $2.75 earnings per share. Medpace's revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities analysts forecast that Medpace will post 12.29 earnings per share for the current fiscal year.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 36,196 shares of Medpace stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the sale, the chief executive officer directly owned 925,799 shares in the company, valued at $440,587,744.10. The trade was a 3.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin M. Brady sold 12,000 shares of Medpace stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the sale, the chief financial officer owned 6,000 shares in the company, valued at $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock worth $74,111,427 over the last ninety days. Company insiders own 20.30% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Sone Capital Management LLC bought a new position in Medpace during the 4th quarter worth approximately $1,318,000. GAMMA Investing LLC lifted its holdings in Medpace by 37.1% during the 1st quarter. GAMMA Investing LLC now owns 307 shares of the company's stock worth $94,000 after buying an additional 83 shares during the last quarter. Fundsmith LLP bought a new position in Medpace during the 4th quarter worth approximately $42,372,000. Hsbc Holdings PLC grew its holdings in shares of Medpace by 157.5% during the first quarter. Hsbc Holdings PLC now owns 4,364 shares of the company's stock valued at $1,296,000 after purchasing an additional 2,669 shares during the last quarter. Finally, Park Avenue Securities LLC grew its holdings in shares of Medpace by 1.8% during the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock valued at $838,000 after purchasing an additional 48 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.